What each study measured
PT-141 Research Found a Small Rise in Desire
First, read the Phase 3 trials, the last big tests before approval. Then see what a 52-week follow-up found about benefits and side effects.
The Main Studies Found a Small Average Gain
Two large trials had women rate desire and distress. PT-141 helped a little more than placebo. None of the women had reached menopause. Low desire caused each woman deep distress.
You'll see later reviewers agreed that the scores changed. They couldn't tell whether daily life felt much different. Animal work first pointed to the brain. A later scan study in women found brain changes too.
Think of the findings as two sides of a scale. Put the small benefit on one side. Put nausea and firm limits on the other, and you can judge the drug.
PT-141 First Changes Activity in the Brain
Animals gave researchers their first hint. PT-141 changed activity in brain cells that help set sexual interest [1]. It didn't start by opening up blood vessels. So researchers turned their attention to the brain.
A later study took 31 women whom low desire had been upsetting. Each woman came in once for the drug and once for a dummy shot, and nobody knew which was which. Their desire held up for as long as 24 hours afterward, the women said. On the scans, an area tied to feelings and one tied to sensing your own body began working more closely together [5].
That's good evidence the brain is where it works. The scan alone doesn't show the change was helpful. What counts is that the women said they felt more desire, and even that can't tell you what you'd feel.
The same family of brain cells also helps control hunger [6]. Related cells in the skin control its color. That may be why repeat use darkens the skin [6].
Bremelanotide Copies a Body Chemical That Wakes Up Brain Cells
Your brain cells carry receptors, which are spots on a cell's surface where a body chemical latches on and gets the cell going. There are five related kinds in this family, and together they help control skin color, hunger and desire [1]. PT-141 attaches to these spots and sets the cell working, much as the body's own chemical would. It mostly reaches the kinds tied to desire.
The common erection pills, which doctors call PDE-5 drugs, work somewhere else. Those pills loosen the blood vessels, which lets the penis fill during arousal. Bremelanotide works in the brain, on wanting sex in the first place [1]. So a PDE-5 drug starts with blood flow, and bremelanotide starts with desire.
Researchers are now testing both drugs together in men whose erections fail. That's a test under way, not a result. The early PT-141 for men work shows how little is known so far.
Two Large PT-141 Trials Beat the Dummy Shot on Both Forms
The two final trials, called Phase 3 studies, took 1267 women. Each woman was put by chance on PT-141 or on a dummy shot. They gave themselves 1.75 mg shots under the skin when they wanted, over 24 weeks [3].
The women filled in two forms, and you can see what each one asked. One asked how much sexual desire they'd felt. Question 13 on the other form was about how much the low desire bothered them. On both, the drug group did a little better than the dummy group. The paper put the odds that luck alone made the gap at under .001 on the desire form, and under .001 on the distress form. In plain terms, that's less than one chance in a thousand each time. So you can believe the gap is real, but it was small.
Forms like these can pick up a small change. They can't show whether a woman's everyday life felt any different. And a group average won't tell you how any one woman, or you, would do.
In animals, female rats on the drug went looking for a mate more often [2]. They didn't show more of every sexual behavior. Male rats and monkeys got erections after the drug [1]. Animal results can't tell you how you'd respond.
The Change Was Real, but Many Women Might Not Feel It
In the Phase 3 studies, desire went up only a little [3]. On question 13, about how upsetting low desire felt, the women moved slightly toward less upset. So the change was real, but not large.
Later reviews wondered if most women would even notice a gain that small [8]. The drug beat the dummy shot. How much that's worth to one woman, or to you, no study can say.
One Reviewer Twice Asked Whether the PT-141 Gain Mattered
In 2021, one reviewer read the Phase 3 results again. He called both changes on the forms small, the same word you've seen all through this page [8]. The forms asked about desire and distress. He doubted that they showed a useful daily change.
In 2024, the same reviewer raised that doubt again [9]. He asked what the scores meant in daily life. You can accept the score change and still ask that question yourself. The two points don't conflict.
In 2022, another PT-141 review covered benefits and harms [10]. It set the two main trials beside a 52-week follow-up [3][4]. The PT-141 papers support one narrow approval. Reviewers still saw only a small average benefit.
PT-141 Mainly Reaches Brain Cells That Shape Desire
Of the five kinds of receptor, the drug works mostly on the one scientists call type 4 [1]. Those spots sit on the brain cells that help set how much you want sex. It reaches a second kind less strongly, and nobody's sure what that adds.
Another kind sits on skin cells and makes your skin darker when switched on. That may be why your skin can darken with frequent use [6].
PT-141 Brain Scans Pointed Away From Blood Flow
PT-141 starts its effect in the brain [1]. Doctors call one common group of erection medicines PDE-5 drugs. Those medicines help blood vessels relax. A stronger erection, if you're a man, doesn't always mean stronger desire.
Women in one study viewed sexual images during brain scans. Their scans changed after the drug [5]. The finding points to brain activity, not wider blood vessels. It still can't promise a useful effect for you.
PT-141 Raised Desire in a Human Scan Study
Animal work first showed more activity in several brain areas [1]. Those areas help shape sexual interest. The drug also changed how the areas worked together. You can't carry that animal finding straight into people.
A later study gave each woman either drug or placebo. Their desire stayed higher through 24 hours [5]. Brain activity changed as sexual pictures appeared on a screen. For you, that's the clearest finding from people.
A 2025 Animal Study Found No Stronger Sexual Reward
In 2025, researchers studied female Syrian hamsters [12]. They looked at a reward system in the brain that runs on dopamine, a natural chemical that drives an animal toward things it likes. Neither a small nor a larger amount of the drug changed those reward cells.
The hamsters also didn't find sex any more rewarding. You can picture how they checked: they watched which of two spaces each animal chose to spend time in.
So in hamsters, the drug doesn't seem to raise desire through that reward system. It settles one narrow question in animals. It doesn't undo what you read about the scans in women.